Wells Fargo has downgraded Cooper Companies Inc (COO) to Equal-Weight from Overweight, a move that suggests increased caution regarding the company's future outlook. This change, effective November 12, 2025, comes as the stock trades at $71.75.
The revision may reflect concerns over competitive pressures, market conditions, or execution risks that could impact Cooper's performance. The company operates in the health care sector, focusing on medical devices through its CooperVision and CooperSurgical segments. CooperVision is known for its contact lens offerings, including MyDay and Biofinity products, while CooperSurgical specializes in fertility and women's health care solutions.
As of November 8, 2025, Cooper Companies holds a market capitalization of $13.7 billion, with a P/E ratio of 33.64 and an EPS of 2.03. The company also offers a dividend yield of 1.8%.
Looking ahead, Cooper is set to report earnings on May 26, 2026, with analysts estimating an EPS of $1.06 and revenue of $1.1 billion. Recent earnings have shown mixed results, with Q3 2025 reporting an EPS of $1.10, exceeding estimates by 1.9%.
Analyst ratings serve as professional opinions based on research and financial models. While they can provide valuable insights, they represent assumptions that may not always materialize. Investment decisions should consider a range of factors, including company fundamentals and industry trends, rather than relying solely on analyst views. The consensus among analysts remains a Buy, with recent actions indicating a spectrum of opinions on Cooper's performance.